Carpenter Technology Corp
Change company Symbol lookup
Select an option...
CRS Carpenter Technology Corp
AMWL American Well Corp
DGLD.NV Credit Suisse AG
HMPQ HempAmericana Inc
$SPMCKCP S&P GSCI Coffee Multiple Contract (U
WYNN Wynn Resorts Ltd
BAC Bank of America Corp
KNDI Kandi Technologies Group Inc
$RFTREES Refinitiv Eurozone ESG Select Index
TCEHY Tencent Holdings Ltd
Go

Materials : Metals & Mining | Small Cap Value
Company profile

Carpenter Technology Corporation is engaged in the manufacturing, fabrication and distribution of specialty metals. The Company develops, manufactures and distributes specialty alloys, including titanium, nickel and cobalt, as well as alloys specifically engineered for additive manufacturing processes and soft magnetics applications. The Company's segments include Specialty Alloys Operations (SAO) and Performance Engineered Products (PEP). Its SAO segment consists of alloy and stainless steel manufacturing operations. Its PEP segment includes the Dynamet titanium business, the Carpenter Powder Products business, the Amega West business, the Specialty Steel Supply business and the Latrobe and Mexico distribution businesses. It provides specialty alloy-based materials and process solutions for applications in the aerospace and defense, energy, transportation, medical and industrial and consumer industries.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$35.70
Day's Change
-0.23 (-0.64%)
Bid
--
Ask
--
B/A Size
--
Day's High
35.99
Day's Low
34.88
Volume
(Heavy Day)
Volume:
636,449

10-day average volume:
466,213
636,449

Supernus to Host Third Quarter 2020 Financial Results Conference Call

5:34 pm ET October 27, 2020 (Globe Newswire) Print

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the third quarter of 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020.

Jack Khattar, President and CEO and the executive management team will host a conference call to present the third quarter 2020 business and financial results on Wednesday, November 4, 2020 at 9:00 a.m. ET. Following management's prepared analysis and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:    (877) 288-1043
International dial-in: (970) 315-0267
Conference ID:         1882244
Conference Call Name:  Supernus Pharmaceuticals Third Quarter 2020 Earnings Conference Call

Following the live call, a replay will be available on the Company's website, www.Supernus.com, in the Investor Relations section. The webcast will be available on the Company's website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR(R) (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR(R) (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN(R) (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC(R) (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO(R) (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 for hypomobility in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.

See full Prescribing Information for our products here: Trokendi XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.

All trademarks are the property of their respective owners.

CONTACTS:

Jack A. Khattar, President and CEO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Or

Investor Contact:

Peter Vozzo

Westwicke, an ICR Company

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.